Back to Search
Start Over
Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma
- Source :
- Journal of Clinical Oncology. 33:e20097-e20097
- Publication Year :
- 2015
- Publisher :
- American Society of Clinical Oncology (ASCO), 2015.
-
Abstract
- e20097 Background: Significant advances have been made in the treatment of stage IV melanoma through the use of targeted therapies in patients (pts) with BRAF V600 mutations. However, there is a cr...
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........7b9e15ff635dbc113e843e6cf4cb7331
- Full Text :
- https://doi.org/10.1200/jco.2015.33.15_suppl.e20097